Kura Oncology Inc. | Mutual Funds
Mutual Funds that own Kura Oncology Inc.
Fidelity Select Biotechnology Portfolio
2,380,817
6.27%
0
0.53%
07/31/2018
Eagle Small Cap Growth Fund
907,377
2.39%
907,377
0.32%
06/29/2018
Vanguard Total Stock Market Index Fund
793,936
2.09%
0
0%
07/31/2018
746,700
1.97%
746,700
0.7%
06/30/2018
SPDR S&P Biotech ETF
651,801
1.72%
1,677
0.23%
09/06/2018
iShares Russell 2000 ETF
519,964
1.37%
-279
0.02%
09/06/2018
iShares Nasdaq Biotechnology ETF
434,058
1.13%
-5,670
0.09%
09/06/2018
Vanguard Extended Market Index Fund
392,748
1.03%
1,100
0.01%
07/31/2018
Fidelity Advisor Biotechnology Fund
325,932
0.86%
-659,670
0.23%
07/31/2018
Candriam Equities L - Biotechnology
305,000
0.8%
-3,000
0.46%
07/31/2018
| Address |
3033 Science Park Road
San Diego California 92121
United States
|
|
Employees
|
- |
| Website |
http://www.kuraoncology.com |
| Updated |
07/08/2019 |
| Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. |
